News | Leads Implantable Devices | August 05, 2019

Abbott Recalls Ellipse Implantable Cardioverter Defibrillators Due to Exposed Aluminum Wires

Exposed aluminum wires identified in Class I recall may prevent defibrillation therapy

Abbott Recalls Ellipse Implantable Cardioverter Defibrillators Due to Exposed Aluminum Wires

August 5, 2019 — Abbott is recalling the Ellipse Implantable Cardioverter Defibrillators (ICDs) because electrical failures have been identified and determined to be due to a faulty manufacturing process, causing some aluminum wires to be partially exposed. ICDs which contain aluminum wires that are not fully insulated are prone to electrical shorting of the capacitor.  The potential patient impact could be the inability to deliver high voltage therapy. There is currently no available method or procedure to determine which of these devices have this issue prior to failure.

Abbott ICDs provide pacing for slow heart rhythms and electrical shock or pacing to stop dangerously fast heart rhythms. These cardiac devices are implanted under the skin in the upper chest area with connecting insulated wires called leads that go into the heart. A patient may need an ICD if their heartbeat is too slow (bradycardia), too fast (tachycardia) or needs coordination to treat heart failure.

On June 21, 2019, Abbott hand-delivered an Urgent Medical Device Recall letter to customers. The letter directed customers to take the following actions:

  • Review the device model and serial numbers to identify the impacted patients and return the acknowledgement form to the sales representative.

Device explant and replacement are recommended. Abbott will work with customers to provide an Abbott replacement device. The recall affects all lots manufactured between April 5 and May 29 of this year; this includes model numbers CD1377-36C, CD1377-36QC, CD1411-36Q, CD2377-36QC, CD2411-36C and CD2411-36Q. 

Abbott is not aware of any related reports of this failure occurring in any affected implanted devices. Of the 108 devices recalled in the U.S., 31 have been implanted. The complaints and MDRs available have either reported that the affected devices have been replaced or are scheduled to be replaced with another ICD generator. None of the complaint or MDRs indicate that any patient harm or adverse events have occurred, and no deaths have been reported.

Healthcare professionals and consumers may report adverse reactions or quality problems they experience using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program either online, by regular mail or by fax to 1-800-FDA-0178. Healthcare professionals employed by facilities that are subject to FDA's user facility reporting requirements should follow the reporting procedures established by their facilities.

For more information: www.cardiovascular.abbott/us/en/hcp/resources/product/advisories.html

 

Related ICD Content

New Technology and Market Challenges Facing Implantable Cardioverter Defibrillators

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD

Use of the Interventional CRT Approach to Solve Issues With LV Lead Placement

New Approaches to EP Lead Management

VIDEO: EP Lead Extraction Strategies


Related Content

Feature | EP Lab | By Vijay Kundekar

Arrhythmias can be described as irregular heart rhythms that are brought on by numerous factors, including heart damage ...

Home August 23, 2022
Home
News | EP Lab

May 24, 2022 — Attune Medical, a pioneering medical device company with a technology platform based on temperature ...

Home May 24, 2022
Home
News | EP Lab

May 4, 2022 — CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home May 04, 2022
Home
News | EP Lab

April 27, 2022 – CathVision, a medical technology company developing innovative electrophysiology solutions designed to ...

Home April 27, 2022
Home
News | EP Lab

Royal Philips, a global leader in health technology, announced late-breaking results of a large-scale, real-world ...

Home April 12, 2022
Home
News | EP Lab

January 14, 2022 — Medtronic has entered into a definitive agreement to acquire Affera Inc., a Boston area-based ...

Home January 14, 2022
Home
News | EP Lab

January 13, 2022 — Abbott received U.S. Food and Drug Administration (FDA) clearance for the EnSite X EP System with ...

Home January 13, 2022
Home
News | EP Lab

January 7, 2022 — Khaldoun Tarakji, M.D., M.P.H., associate section head of cardiac electrophysiology at the Heart ...

Home January 07, 2022
Home
News | EP Lab

January 5, 2022 — Stereotaxis announced a recent publication in Frontiers in Cardiovascular Medicine titled “Atrial ...

Home January 05, 2022
Home
Feature | EP Lab

Children’s Hospital Los Angeles cardiologist Michael Silka, M.D., helped to pioneer the development of indications for ...

Home December 07, 2021
Home
Subscribe Now